Unknown

Dataset Information

0

Salvage therapy of multiple myeloma: the new generation drugs.

ABSTRACT: During the past decade, overall results of treatment of multiple myeloma (MM) have been improved and survival curves are now significantly better with respect to those obtained with historical treatment. These improvements are linked to a deeper knowledge of the biology of disease and to the introduction in clinical practice of drugs with different mechanism of action such as proteasome inhibitors and immunomodulatory drugs (IMiDs). However, MM remains in most cases an incurable disease. For patients who relapse after treatment with novel agents, the prognosis is dismal and new drugs and therapeutic strategies are required for continued disease control. In this review, we summarize new insights in salvage therapy for relapsed/refractory MM as emerging from recent clinical trials exploring the activity of bendamustine, new generation proteasome inhibitors, novel IMiDs, monoclonal antibodies, and drugs interfering with growth pathways.

SUBMITTER: Romano A 

PROVIDER: S-EPMC4055245 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

During the past decade, overall results of treatment of multiple myeloma (MM) have been improved and survival curves are now significantly better with respect to those obtained with historical treatment. These improvements are linked to a deeper knowledge of the biology of disease and to the introduction in clinical practice of drugs with different mechanism of action such as proteasome inhibitors and immunomodulatory drugs (IMiDs). However, MM remains in most cases an incurable disease. For pat  ...[more]

Similar Datasets

Unknown Salvage second transplantation in relapsed multiple myeloma.
| S-EPMC8020391 | biostudies-literature
Unknown p38 Molecular Targeting for Next-Generation Multiple Myeloma Therapy.
| S-EPMC10813990 | biostudies-literature
Unknown Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.
| S-EPMC10082354 | biostudies-literature
Unknown Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma.
| S-EPMC8392190 | biostudies-literature
Unknown A new prognostic scoring system for newly diagnosed multiple myeloma in the era of new drugs.
| S-EPMC11536264 | biostudies-literature
Unknown Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
| S-EPMC6280981 | biostudies-literature
Unknown Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma.
| S-EPMC9911829 | biostudies-literature
Unknown Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.
| S-EPMC5682004 | biostudies-literature
Unknown CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma.
| S-EPMC8197914 | biostudies-literature
Unknown New therapies in multiple myeloma.
| S-EPMC2779346 | biostudies-other